Why Companies Are Choosing To Manufacture Biopharmaceuticals In Australia

World-class researchers and state-of-the-art facilities, a streamlined regulatory framework, and generous tax incentives have made Australia a prime location for the biotech industry.

Over the past decade, Australia has become a global leader in life science research and biologics manufacturing. Generous tax incentives and government funding are further strengthening its position as a prime location for biotech companies.

Placed 17th in 2010, Australia has jumped to fifth (out of 54 countries) in global biotechnology¹, outperforming countries like the United Kingdom, Germany, and Canada.

Australia is home to more than 400 locally-owned biotechnology and 500 MedTech companies, and with around 50 multinationals operating subsidiaries in Australia, including GSK, Merck, Pfizer, Bristol-Myers Squibb, and Novartis, the Australian life sciences sector is valued at over AU$100 billion.